Treatment of benign prostatic hyperplasia and erectile dysfunction with tadalafil in the general practice
Abstract
Lower urinary tract symptoms and benign prostatic hyperplasia are extremely common in aging men. Recently, more and more attention has been paid to the relationship between LUTS symptoms and erectile dysfunction, because LUTS and ED are very common and often coexist in the same group of aging men (especially after the age of 50) and have significant impact on overall quality of life. Phosphodiesterase 5 (PDE5-i) inhibitors have been used in the treatment of LUTS in the course of BPH, and primarily in the treatment of ED. PDE5-i can be used in patients with moderate or severe LUTS symptoms in the course of BPH with or without ED. Although clinical trials of several selective oral PDE5Is have been performed in men with LUTS, only tadalafil 5 mg once daily has been approved for the treatment of male LUTS. Clinical observations to date indicate that younger men with a low body mass index and more severe LUTS symptoms benefit most from PDE5-i treatment. Long-term experience with the use of tadalafil in men with LUTS is limited to one clinical trial with one year follow-up, therefore no conclusions on its efficacy or tolerance beyond one year are possible.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.